This series features KU Medical Center's nationally recognized experts speaking about emerging issues. Conveniently scheduled on Tuesdays from 12:00 Noon - 1:00 p.m. and without charge. Emerging Trends is designed to inspire faculty, staff, students and others to incorporate state-of-the-art knowledge in their clinical and organizational practices. Registration is on-site only. Seating is on a space-available basis. Nurses and physicians can earn contact hours.
All sessions are at KU Medical Center, 3901 Rainbow Blvd., Kansas City, Kan. See the session for the room. A campus map is available at: http://www.kumc.edu/Pulse/map.html and paid parking is available in the Olathe and Cambridge Parking Facilities. Bring your own lunch, and join in the discussion about these exciting new trends.
Sponsored by KU HealthPartners, Inc. and the University of Kansas School of Nursing. Co-sponsored by Health Policy & Management, School of Medicine, University of Kansas Medical Center.
Contact: Mary L. Gambino, (913) 588-1695 or mgambino@kumc.edu
If you would like to receive e-mail updates for these programs, please send your request to mgambino@kumc.edu
For continuing education information: Click Here
Metastasis and relapse of disease are the main killers in cancer. Surgically and chemotherapeutically removed tumors reappear in months to a few years, become resistant to anti-tumor agents or radiotherapy, and spread to multiple organs resulting in shortened life expectancy.
The cancer “stem cell” concept has been around since 1889 when Stephen Paget proposed the “Seed and Soil” hypothesis of cancer pathology. Although the term “stem cell” (stammzelle) was first used by German Biologist Ernst Haeckel in 1868, it has taken several decades for cancer biologists to realize the “stem” characteristics of cancer cells that are resistant to therapy and tend to metastasize. The evidence for this hypothesis, resistance of cancer “stem” cells to current drugs, and the need for discovering novel cancer treatment modalities will be discussed and reviewed in this seminar.
At the completion of this program, participants should be able to
Date: |
Tuesday, February 16, 2010 |
Time: |
Noon - 1:00 p.m. |
Location: |
1050 School of Nursing |
Fee: |
Free |
Faculty: |
G. Sitta Sittampalam, PhD, Professor, Pharmacology, Toxicology and Therapeutics; Deputy Director, Office of Therapeutics, Discovery and Development; & Co-Leader, Drug Discovery and Experimental Therapeutics Research Program, University of Kansas Cancer Cente |
Sittampalam received his PhD in Analytical Chemistry from the University of Arizona in 1982. He joined KUMC in September 2007 to assist in overseeing a fully integrated drug discovery and development program through collaboration of researchers, industry partners, regulatory and technology transfer resources. Sitta Sittampalam, PhD brings over 23 years of pharmaceutical industry experience at Eli Lilly & Company to help lead the Office of Therapeutics, Discovery and Development. His exceptional experience and background in drug discovery and assay development helps to foster the University of Kansas Cancer Center’s (KUCC) effort to attain its goal of being the number one academic generator of oncology drugs. Sittampalam joined Eli Lilly & Company in 1984, as a Senior Analytical Chemist in the Analytical Development Division. From 1989-2001, he assumed a series of senior positions in Biochemical Pharmacology to Bio Research Technologies Division at Lilly. In 2001, Sittampalam was named Head of the Lead Optimization Biology Laboratory where he oversaw lead generation and lead optimization and candidate selection efforts. In 2007, he resumed the role of Senior Research Advisor where he lead the Cell Technology group to develop an adult stem/progenitor cell-based screening platform for High Content Phenotypic Screening. In 2005, Sittampalam wrote and edited, “Assay Guidance Manual”, which is published and used by the National Institutes of Health as part of its RoadMap Program. His research interests are in developing innovative methods in quantitative biology, stem cell pharmacology and its applications in drug discovery. Of special interest is the integration of state-of-the-art cell high content imaging technologies and high throughput screening with engineered 3D tissues to identify and validate novel drug targets in cancer. Engineered 3D tumors grown from cancel cell lines will also serve as physiologically relevant in-vitro models for testing efficacy differences of existing anti-cancer agents, and the discovery of new more effective agents in pre-clinical models. Current research also involves isolation and characterization of circulating tumor cells (CTC) and cancer stem cells (CSC). They are believed to contribute to relapse and metastasis. We believe that a thorough understanding of the biology and pharmacology of these cells, and their response to known anti-tumor agents will advance the development of better agents to treat cancer. The detection of circulating tumor cells as diagnostic and prognostic biomarkers of metastasis is another area of interest. In addition, we are also developing methods to isolate and culture these rare cells for use in drug discovery applications. |
According to the National Heart, Lung, and Blood Institute's National Center on Sleep Disorders Research (NCSDR), about 70 million Americans suffer from sleep problems, and of those, nearly 60 percent have a chronic disorder. Each year, sleep disorders, sleep deprivation, and sleepiness add an estimated $15.9 billion to the national health care bill. Additional costs to society for related health problems, lost worker productivity, and accidents have not been calculated. Sleep disorders and disturbances of sleep comprise a broad range of problems, including sleep apnea, narcolepsy, insomnia, parasomnia, jet-lag syndrome, and disturbed biological and circadian rhythms.
Insomnia, for example, occurs in about one third of the adult population. Insomnia symptoms include difficulty initiating sleep, difficulty maintaining sleep, early morning awakening, and nonrestorative sleep. It has been determined to be more common among women, middle-aged and older adults, shift workers, and people with medical or psychiatric disorders.
Join us to learn what sleep disorder research will do to improve patient care for this population.
Date: |
Tuesday, April 20, 2010 |
Time: |
Noon - 1:00 p.m. |
Location: |
1050 School of Nursing |
Fee: |
Free |
Faculty: |
Bob Whitman, PhD, Director of Pulmonary Function Lab, Sleep Disorders Center, Cardiopulmonary Rehab., & Neuropsychology |
| Dr. Whitman, a certified sleep specialist, has worked with sleep disorders for more than 30 years. |
Overview:
By the end of this session, participants will be able to:
Date: |
Tuesday, September 21, 2010 |
Time: |
Noon - 1:00 p.m. |
Location: |
TBD |
Fee: |
Free |
Faculty: |
Randolph Nudo , PhD, Professor, Molecular and Integrative Physiology; Director, Landon Center on Aging |
| Dr. Nudo received his PhD from Florida State University in 1985. The focus of his research is the brain's capacity for self-repair after damage utilizing both non-human primate and rodent models of stroke recovery to determine the neurophysiologic, neuroanatomic, biochemical and molecular bases for recovery. By tracking changes in the structure and function of motor areas of the cerebral cortex as a result of a focal vascular infarct, he is beginning to describe the cascade of events that give rise to the reorganized brain. He also studies novel forms of treatment in chronic stroke to enhance and accelerate the recovery process. These treatment interventions include physiotherapy, pharmacotherapy, or electrical stimulation therapy either alone or in combination. A goal is to use these interdisciplinary approaches to translate directly the information gained through brain plasticity research into effective clinical applications. |
By the end of this session, participants will be able to:
Date: |
Tuesday, October 19, 2010 |
Time: |
Noon - 1:00 p.m. |
Location: |
TBD |
Fee: |
Free |
Faculty: |
Buddhadeb Dawn , MD, FACC, FAHA, Director, Cardiovascular Diseases and the Cardiovascular Research Institute |
Dawn is widely recognized for his research using adult bone marrow and cardiac stem cells to generate new, healthy tissue to repair the damaged heart after a heart attack. Prior to accepting his new position, Dr. Dawn served as a professor of medicine in the Division of Cardiology at the University of Louisville School of Medicine in Kentucky, the director of the Chest Pain Center at the University of Louisville Hospital, as well as a staff physician in several Louisville-area hospitals. His research has been funded by the National Institutes of Health as well as the American Heart Association. |
According to conventional wisdom, aging is inescapable and irreversible. Molecules, cells, and organs are all affected negatively by aging, and the incidence of certain diseases are also positively correlated to aging, e.g. arthritis, osteoporosis, cancer, dementia. While eternal youth has been long sought after, most of the early searching was for an external elixir or healing water, i.e., fountain of youth.
Many theories have been promulgated about aging, and have led to two major classifications. The first, programmed aging, suggests that every organism has control mechanisms within them that dictates elderliness and deterioration. The alternative classification suggests that aging is due to wear and tear, which is summative from things like radiation damage, chemical toxins, metal ions, free-radicals, etc. Damage from such substances affects genes, proteins, cell membranes, enzyme function, and other structures.
New evidence is beginning to shed light on aging that may in the near future impact patient care. The purpose of this session is provide health care professionals an update on the evidence and discuss the ongoing developments that health care professionals need to be aware of in their practice.
By the end of this session, the participant will be able to:
Date: |
Tuesday, November 16, 2010 |
Time: |
Noon - 1:00 p.m. |
Location: |
TBD |
Fee: |
Free |
Faculty: |
B. T. Zhu , PhD, Professor, Pharmacology, Toxicology and Therapeutics |
| Dr. Zhu received his PhD in 1993 from the University of Texas Medical Branch. His research interests include:
1. Carcinogenic and anticancer actions of various endogenously-formed estrogen metabolites. 2. Physiological actions exerted by the endogenous estrogen metabolites. 3. Pharmacological actions of naturally-occurring compounds (such as dietary phenolic antioxidants and fatty acids) and their potential use as therapeutic agents in humans. |
May 5, 2009: The 2009 H2N1 Influenza Outbreak: What Every Healthcare Professional Needs to Know with Daniel Hinthorn, MD.
View presentation at: http://www2.kumc.edu/son/nce/Podcasts/H1N1_Update_050509.wmv
Resources:
©
The University of Kansas Medical Center